Burkholderia Genome Sequencing and Analysis

Burkholderia Genome Sequencing and Analysis

You are here

We developed some of the earliest annotated genome sequences for the genus Burkholderia including the biothreat agents Burkholderia mallei and Burkholderia pseudomallei. We expanded on our genome sequencing efforts to include efforts in whole genome gene expression analysis and functional analysis of genome variation. We also sequenced several members of the Burkholderia cenocepacia complex that are important pathogens in the lungs of cystic fibrosis patients.

Publications

The In vitro Antibiotic Tolerant Persister Population in Burkholderia pseudomallei is Altered by Environmental Factors.
Frontiers in microbiology. 2015-01-01; 6.1338.
PMID: 26696964
The tandem repeats enabling reversible switching between the two phases of β-lactamase substrate spectrum.
PLoS genetics. 2014-09-01; 10.9: e1004640.
PMID: 25233343
Sequence Determination of Burkholderia pseudomallei Strain NCTC 13392 Colony Morphology Variants.
Genome announcements. 2013-11-07; 1.6:
PMID: 24201202
Draft Genome Sequences of Burkholderia cenocepacia ET12 Lineage Strains K56-2 and BC7.
Genome announcements. 2013-10-17; 1.5:
PMID: 24136849
Draft genome sequence determination for cystic fibrosis and chronic granulomatous disease Burkholderia multivorans isolates.
Journal of bacteriology. 2012-11-01; 194.22: 6356-7.
PMID: 23105085
Twelve positions in a β-lactamase that can expand its substrate spectrum with a single amino acid substitution.
PloS one. 2012-01-01; 7.3: e37585.
PMID: 22629423
Simple sequence repeat (SSR)-based gene diversity in Burkholderia pseudomallei and Burkholderia mallei.
Molecules and cells. 2009-02-28; 27.2: 237-41.
PMID: 19277507
Genomic islands from five strains of Burkholderia pseudomallei.
BMC genomics. 2008-11-27; 9.566.
PMID: 19038032
Characterization of clinically-attenuated Burkholderia mallei by whole genome sequencing: candidate strain for exclusion from Select Agent lists.
PloS one. 2008-04-30; 3.4: e2058.
PMID: 18446194

Funding

Funding for this project provided through the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID).